Lumeblue 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0004 
Update of section 4.2 of the SmPC in order to 
25/05/2023 
11/09/2023 
SmPC 
SmPC new text: 
introduce a new posology regimen based on scientific 
The total dose of the medicinal product must be taken 
literature and PK/PD results from studies CB-17-
01/17 and CB-17-01/15; CB-17-01/17 is an open-
label, randomized, cross-over, safety and 
bioavailability descriptive study in healthy volunteers 
receiving a full and a split dose regimen of bowel 
cleansing preparation for colonoscopy; CB-17-01/15 
orally during or after the intake of low-volume (e.g. 2 L) or 
high-volume (e.g. 4 L) polyethylene glycol (PEG) based 
bowel cleansing preparation and should be completed the 
evening prior to the colonoscopy to ensure there is enough 
time for the tablets to reach the colon and locally release 
the methylthioninium chloride prior to the colonoscopy. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
is a single dose, randomised, parallel groups, open 
label, efficacy study in patients receiving a split dose 
regimen of bowel cleansing preparation for 
colonoscopy. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
The patient should take the medicinal product with the low-
volume (e.g. 2L) or high-volume (e.g. 4 L) PEG based 
bowel cleansing regimen chosen by the healthcare provider 
according to the same dosing schedule. 
For more information, please refer to the Summary of 
Product Characteristics. 
IB/0003/G 
This was an application for a group of variations. 
24/11/2021 
n/a 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
T/0002 
Transfer of Marketing Authorisation 
08/04/2021 
21/05/2021 
SmPC, 
Labelling and 
PL 
IAIN/0001/G 
This was an application for a group of variations. 
15/12/2020 
19/05/2021 
SmPC, Annex 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
A.2.a - Administrative change - Change in the 
(invented) name of the medicinal product for CAPs 
II, Labelling 
and PL 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
